Please login to the form below
Forixiga
This page shows the latest Forixiga news and features for those working in and with pharma, biotech and healthcare.
AZ gets US approval for diabetes combo Qtern
Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin).
Latest news
-
EU clears AZ's FDA-rejected diabetes combination
Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after
-
FDA rejects AZ's diabetes combination
The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
